IL6 and hepatocellular carcinoma: In addition, regarding the HCT-116 cell line, Niu and colleagues have recently reported that the SAS-related p16/IL6 axis, in parallel with an AKT phosphorylation activation, contributes to the formation of acquired resistance in hepatocellular carcinoma cells receiving long-term exposure to sorafenib, another MKI [43].